Compass Therapeutics, Inc. (CMPX)

Quarterly Report Filed: 2026-05-05

The filing contains extensive structured data across multiple therapeutic programs (CTX10726, CTX8371, CTX471, Tovecimib) and strategic partnerships (Adimab, ABL Bio agreements), indicating an active pipeline development phase with ongoing R&D investments.
Presence of recent equity financing activity in August 2025 (underwriting agreement with pre-funded warrants and overallotment options) suggests the company raised capital to fund operations, which is typical for clinical-stage biopharmaceutical companies without product revenues.
The document reflects multiple fair value measurement categories for investment securities and structured hedging arrangements, indicating careful treasury management and liquidity preservation strategies common among pre-revenue biotech firms managing cash burn.
Significant presence of RSU and stock option data across multiple plans (2020 Stock Option and Incentive Plan, Inducement Plan) demonstrates ongoing employee retention efforts, which is critical for biotech companies competing for specialized scientific talent.

Current Report Filed: 2026-05-05

Compass Therapeutics reported Q1 2026 financial results on May 5, 2026, with the detailed press release attached as Exhibit 99.1 but not disclosed in this filing summary.
The filing was signed by Neil Lerner, Chief Accounting Officer, indicating standard quarterly earnings disclosure procedures without executive leadership commentary.
As a NASDAQ-listed biopharmaceutical company, Compass Therapeutics maintains emerging growth company status but has not elected extended transition periods for accounting standards compliance.

Insider Trading Filed: 2026-04-29

General Counsel Jonathan Anderman acquired 25,000 shares of common stock at $1.89 per share on 04/29/2026, increasing his direct beneficial ownership to 196,000 shares, demonstrating insider confidence in the company at current valuation levels.
The acquisition includes 150,000 unvested restricted stock units (RSUs) granted on January 2, 2026, with four-year service-based vesting and first installment vesting on January 2, 2027, indicating significant long-term incentive alignment with company performance.
The stock price of $1.89 at time of purchase suggests the company may be trading at depressed valuations, which could indicate either market weakness or a buying opportunity depending on company fundamentals and pipeline progress.

Insider Trading Filed: 2026-04-29

Chief Accounting Officer Neil Lerner purchased 15,000 shares at $1.89 on April 29, 2026, indicating insider confidence in the company at this price point.
Lerner's total beneficial ownership reached 397,500 shares following this transaction, with 62,500 shares comprising unvested RSUs granted January 2, 2026, vesting over four years in equal annual installments.
The insider purchase represents a modest investment of approximately $28,350, which is a relatively small transaction that suggests either limited conviction or capital constraints rather than major confidence signaling.
RSU vesting schedule shows first tranche vested on January 2, 2027, indicating Lerner's compensation alignment with long-term company performance over the four-year vesting period.

Current Report Filed: 2026-04-27

Tovecimig met its primary endpoint with a statistically significant 17.1% ORR vs 5.3% for paclitaxel alone (p=0.031) in second-line BTC, demonstrating meaningful clinical benefit and de-risking the Phase 2/3 program.
Progression-free survival showed strong results (4.7 months vs 2.6 months, HR=0.44, p<0.0001), but overall survival failed to meet the secondary endpoint due to 54% crossover from control arm, complicating the clinical picture and potentially affecting regulatory pathway.
Post-hoc analyses of crossover patients show tovecimig efficacy (median OS 12.8 months vs 6.1 months for non-crossover controls, p=0.04), suggesting the drug works but the trial design with high crossover limited OS assessment and may complicate approval discussions with FDA.
The company announced these results via press release and webcast on April 27, 2026, indicating confidence in data disclosure and proactive investor communication regarding both positive and challenging trial aspects.

Annual Report Filed: 2026-03-05

Compass Therapeutics, Inc. (CMPX) reported strong financial performance in FY 2025, with increases in both research and development as well as general and administrative expenses compared to the prior year.
The company continued to advance its pipeline, including late-stage clinical trials for its lead drug candidates CTX10726, CTX8371, and Tovecimig.
Compass Therapeutics raised additional capital through an underwritten public offering in August 2025, which included the issuance of pre-funded warrants, providing the company with additional financial resources to support its operations and pipeline development.

Current Report Filed: 2026-03-05

Compass Therapeutics reported full-year 2025 financial results, indicating the company's operations and financial condition for the year.
The company did not provide any forward-looking guidance or commentary on its business performance and outlook.
There were no major announcements or disclosures of material events or agreements in this 8-K filing.

Insider Trading Filed: 2026-02-10

The reporting person, Thomas J. Schuetz, who is the Chief Executive Officer and a Director of Compass Therapeutics, Inc. (CMPX), has disposed of 36,687 shares of the company's common stock through a tax withholding transaction.
Schuetz continues to beneficially own a significant number of shares (6,603,336) in the company, indicating his commitment and alignment with shareholders.
The transaction involves the vesting of restricted stock units (RSUs) granted to Schuetz in 2023, 2024, and 2026, which are subject to service-based vesting conditions.

Insider Trading Filed: 2026-01-12

The CEO of Compass Therapeutics, Inc. (CMPX) has disposed of 46,777 shares by having them withheld to cover tax withholding obligations, potentially indicating some insider selling activity.
The CEO still holds a significant number of restricted stock units (RSUs) in the company, with 250,000 RSUs granted in 2023, 318,750 RSUs granted in 2024, and 250,000 RSUs granted in 2026, suggesting a continued long-term alignment with shareholders.
The vesting schedule of the CEO's RSUs is spread out over multiple years, with the first installments vesting in 2024, 2025, and 2027, respectively, indicating a focus on long-term performance.

Current Report Filed: 2026-01-06